ITPRID2

Across TCGA pan-cancer cohorts, ITPRID2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITPRID2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ITPRID2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ITPRID2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where ITPRID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	54	view →
LUAD	DFS	Median	All	0.824	0.976	.010	34	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.477	.018	16	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.943	.035	5	view →
LSCC	DFS	Quartile	II,III,IV	0.221	0.888	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITPRID2–CCRCC (DFS)

Open the CCRCC breakdown →